<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333928</url>
  </required_header>
  <id_info>
    <org_study_id>HTD1801.PCT003</org_study_id>
    <nct_id>NCT03333928</nct_id>
  </id_info>
  <brief_title>A POC and Dose-Ranging Study of HTD1801 in PSC Patients</brief_title>
  <official_title>A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in
      adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and
      placebo, bid.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A primary parallel group comparison for a 6-week treatment, followed by a 6-week dose-controlled extension, and followed by a 6-week random withdrawal.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of alkaline phosphatase (ALP)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of alkaline phosphatase (ALP)</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and severity of adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and severity of adverse events</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PK/PD (substudy)</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Primary Sclerosing Cholangitis (PSC)</condition>
  <arm_group>
    <arm_group_label>500mg HTD1801, bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg HTD1801, bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801</intervention_name>
    <description>HTD1801 tablets, 250mg</description>
    <arm_group_label>1000mg HTD1801, bid</arm_group_label>
    <arm_group_label>500mg HTD1801, bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets manufactured to mimic HTD1801 tablets</description>
    <arm_group_label>placebo, bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 75 years of age;

          -  Have a clinical diagnosis of PSC as evident by chronic cholestasis of more than six
             months duration with either a consistent magnetic resonance cholangiopancreatography
             (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing
             cholangitis;

          -  If subjects have Inflammatory Bowel Disease (IBD) they will be eligible to
             participate. If a subject has IBD, documented evidence of IBD must have been evident
             by prior endoscopy or in previous medical records for ≥6 months. In addition, subjects
             may only enter the study with a Partial Mayo Score of 0-4, inclusively. Subjects who
             are on treatment are allowed, provided they are stable for 3 months if taking:

               1. 5-amino salicylic acid drugs,

               2. azathioprine,

               3. 6-mercaptopurine, or methotrexate

               4. biologics;

          -  Have a serum ALP ≥1.5 × upper limit of normal (ULN);

          -  Be able to understand and sign a written informed consent form (ICF);

          -  Subjects receiving allowed concomitant medications need to be on stable therapy for 28
             days prior to the Baseline visit, with the exception of ursodeoxycholic acid (UDCA),
             which should be stable for at least 6 weeks prior to the Baseline visit.

        Exclusion Criteria:

          -  Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis,
             recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis,
             surgical or blunt abdominal trauma, recurrent pyogenic cholangitis,
             choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other
             cause of secondary sclerosing cholangitis) on prior clinical investigations;

          -  Small duct PSC;

          -  Presence of percutaneous drain or bile duct stent;

          -  History of cholangiocarcinoma or clinical suspicion of new dominant stricture within 1
             year by MRCP/ERCP. Presence of dominant stricture without ERCP evidence of
             cholangiocarcinoma is acceptable if stable for ≥ 1 year;

          -  Ascending cholangitis within 60 days prior to Screening;

          -  History of alcohol or substance abuse or dependence;

          -  Prior or planned liver transplantation;

          -  Presence of alternative causes of chronic liver disease, including alcoholic liver
             disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune
             hepatitis;

          -  Platelet count below 125,000/mm3, albumin below 3.0 g/dL, International Normalized
             Ratio (INR) &gt; 1.2, or a history of ascites, or encephalopathy, or history of
             esophageal variceal bleeding;

          -  Severe active IBD or flare in colitis activity within the last 90 days requiring
             intensification of therapy beyond baseline treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Di Bisceglie, MD,FACP,FAASLD</last_name>
    <role>Study Director</role>
    <affiliation>HighTide Therapeutics USA, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fresno Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck School of Medicine of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Denver Gastroenterology, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Medicine University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Woods Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3H 0V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Centre for Liver Disease, Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

